MAdCAM-1

MAdCAM-1 Overview

English NameMucosal addressin cell adhesion molecule-1Approved Drugs1
Drugs in Clinical Trials4Target SynonymMucosal addressin cell adhesion molecule 1,MADCAM1,hMAdCAM-1,Mucosal Vascular Addressin Cell Adhesion Molecule 1,MACAM1,MAdCAM-1,Mucosal Addressin Cell Adhesion Molecule-1
Highest Development StageApproved
English NameMucosal addressin cell adhesion molecule-1
Target SynonymMucosal addressin cell adhesion molecule 1,MADCAM1,hMAdCAM-1,Mucosal Vascular Addressin Cell Adhesion Molecule 1,MACAM1,MAdCAM-1,Mucosal Addressin Cell Adhesion Molecule-1
Approved Drugs1
Drugs in Clinical Trials4
Highest Development StageApproved

MAdCAM-1 Product List

  • Product Category

    Protein (7)Cell (1)

  • Product Status

    Launched (8)

  • Species

    Human (4)Cynomolgus (2)Mouse (2)

  • Tag

    Fc Tag (1)Fc Tag & Avi Tag (1)His Tag (3)His Tag & Avi Tag (2)- (1)

  • Conjugate

    Unconjugated (4)Biotin-labeled (3)- (1)

MAdCAM-1 Background

The mucosal addressin cell adhesion molecule-1 (MAdCAM-1) takes a key role in the endothelial adhesion and migration of lymphocytes to sites of inflammation in inflammatory disease. In vitro and in vivo data indicate that blockade of the adhesion molecule mucosal address in cell adhesion molecule (MAdCAM) pathway decreases leukocyte homing to the gut by inhibiting the interaction between MAdCAM and its ligand the α4β7 integrin expressed on lymphocytes.

MAdCAM-1 Synonyms

MAdCAM-1,MAdCAM1,Mucosal vascular addressin cell adhesion molecule 1 transcript variant 1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
OntamalimabSHP-647; PF-00547659; PF-547659Phase 3 ClinicalPfizer IncColitis, Ulcerative; Crohn Disease; Fatty Liver; Ileitis
Details
Vedolizumab biosimilar (Polpharma Biologics)PB-016Phase 3 ClinicalPolpharma Biologics SaColitis, Ulcerative; Crohn Disease; Pouchitis
Details
Vedolizumab Biosimilar (Intas Pharmaceuticals)INTP-53; INTP53Phase 3 ClinicalIntas Pharmaceuticals LtdColitis, Ulcerative
Details
Vedolizumab biosimilar (Alvotech)AVT-16; AVT16Phase 1 ClinicalAlvotech Swiss AgColitis, Ulcerative; Immune System Diseases
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
VedolizumabMLN-0002; LPD-02; MLN-002; MLN-02; LDP-02ApprovedMillennium Pharmaceuticals IncEntyvio, Entyvio Pen, Kynteles, 安吉优United StatesColitis, Ulcerative; Crohn DiseaseTakeda Pharmaceuticals USA Inc2014-05-20Carcinoma, Non-Small-Cell Lung; Celiac Disease; Cholangitis, Sclerosing; Colitis; Colitis, Ulcerative; Crohn Disease; Gastritis; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Inflammatory Bowel Diseases; Melanoma; Neoplasms; Pediatric Crohn's disease; Pediatric ulcerative colitis; Pouchitis; Solid tumours; Urogenital Neoplasms
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information